Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.

Korjian, Serge; Braunwald, Eugene; Daaboul, Yazan; Verheugt, Freek WA; Bode, Christoph; Tendera, Michal; Jain, Purva; Plotnikov, Alexei; Burton, Paul; Gibson, C Michael

doi:10.1177/2048872617745003

Record: found
Abstract: found
Article: not found

Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.

Author(s): Serge Korjian ¹ , Eugene Braunwald ² , Yazan Daaboul ¹ , Freek Verheugt ³ , Christoph Bode ⁴ , Michal Tendera ⁵ , Purva Jain ¹ , Alexei Plotnikov ⁶ , Paul Burton ⁶ , C Michael Gibson ¹

Publication date (Electronic): Mar 2019

Journal: European heart journal. Acute cardiovascular care

Publisher: SAGE Publications

Keywords: Acute coronary syndrome, biomarker positive, dual antiplatelet therapy, dual pathway, novel oral anticoagulants, rivaroxaban, secondary prevention, stroke

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Despite dual antiplatelet therapy, persistent thrombin generation and thrombin-mediated platelet activation account in part for the residual risk of atherothrombotic disease among patients with prior acute coronary syndrome (ACS). Inhibition of thrombin generation among high-risk ACS patients (biomarker-positive ACS) with the factor Xa inhibitor rivaroxaban may limit ongoing thrombus formation and myocardial necrosis and thereby improve clinical outcomes.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur Heart J Acute Cardiovasc Care

Title: European heart journal. Acute cardiovascular care

Publisher: SAGE Publications

ISSN (Electronic): 2048-8734

ISSN (Print): 2048-8726

Publication date (Electronic): Mar 2019

Volume: 8

Issue: 2

Affiliations

[1 ] 1 PERFUSE Study Group. Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

[2 ] 2 TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

[3 ] 3 Radboud University, Nijmegen University Medical Center, Nijmegen, The Netherlands.

[4 ] 4 University Hospital Freiburg, Freiburg, Germany.

[5 ] 5 Medical University of Silesia, Katowice, Poland.

[6 ] 6 Johnson & Johnson Pharmaceutical Research and Development, Raritan.

Article

DOI: 10.1177/2048872617745003

PubMed ID: 29249166

SO-VID: 8ef16eea-5ccd-4a13-aae8-f90c39250ac5

History

Keywords: Acute coronary syndrome,biomarker positive,dual antiplatelet therapy,dual pathway,novel oral anticoagulants,rivaroxaban,secondary prevention,stroke

Data availability:

Keywords: Acute coronary syndrome, biomarker positive, dual antiplatelet therapy, dual pathway, novel oral anticoagulants, rivaroxaban, secondary prevention, stroke

Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.

Read this article at

Abstract

Related collections

Efficacy of Communicating Science

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 238

Cited by 4